TeamDrive
RUS

Pharma ads at the Winter Olympics: 15 brands, but midpack finish for spending share

13 March 2018

Beth Snyder Bulik / FiercePharma

Pharma ads skated into the Winter Olympics along with dozens of consumer brand ads, and although they weren’t in any medal contention for time and attention, the category had a respectable showing.

Fifteen prescription drug brand ads ran 221 times on national TV during the February run of the PyeongChang games on NBC, according to data from real-time TV ad tracker iSpot.tv. In terms of spend, prescription drug ads represented a 4.1% Spend Share of Voice for all ads that ran during the Olympic ad-tracking period from Feb. 1 to Feb. 26, iSpot reported.

iSpot is not releasing specific advertising spending categories or overall TV spending figures for the Winter Olympics, but in early February, NBC released a statement saying it had surpassed $900 million in national ad sales for the PyeongChang Olympics, a Winter Games record.

The top three pharma ads came from Merck and Pfizer, with one from Merck and two from Pfizer. Merck spent $11.3 million on cancer drug Keytruda and a commercial that chronicles the journey of real-life patient Donna, according to iSpot.tv. That ad, the company's first real patient TV ad for Keytruda, has been running since September, and Merck has spent more than $76 million in national ad runs to date, according to iSpot data.

Meanwhile, Pfizer at the Olympics spent $10.9 million on commercials for its metastatic breast cancer treatment Ibrance and another $8.3 million on a Xeljanz XR spot for its rheumatoid arthritis indication.

Overall, drug company advertising frequency and share of spend at the Winter Games paled in comparison to top category advertisers such as auto brands and mobile electronics, but pharma did come in around the same spending share levels as other mid-level categories, such as retail stores and travel category brands.

Source


Previous publication Next publication

Media Center

  • 19 September 2018

    Russia approves new state strategy for pharmaceutical industry

    A new state strategy for the development of the domestic pharmaceutical industry, known as "Strategy for the development of the pharmaceutical industry of Russia until 2030," has been recently approved by the Russian Ministry of Industry and Trade, with the aim to bring the Russian pharmaceutical production to a new level.

  • 18 September 2018

    The Ministry of Health of the Russian Federation improves patent protection law

    The Ministry of Health of Russia has published a notification on the development of amendments to Federal Law No. 61 of 12.04.2010 “On circulation of medicinal products”, designed to synchronize it with regulatory acts of the Eurasian Economic Union. The procedure for registration of the medicinal product will be corrected.

  • 17 September 2018

    GlobalData published new report on the Top 25 pharma companies

    The performance highlights of the Top 25 publicly traded global pharmaceutical companies by Market Cap (Mcap) for the quarter ended June 30, 2018 (Q2), compared to the quarter ended March 31, 2018 (Q1), have been analyzed in the latest research from GlobalData, a leading data and analytics company.

  • 14 September 2018

    US scientists conduct clinical trial of influenza vaccine with imiquimod

    A Phase 1 clinical trial examining whether a topical cream can enhance the immune response conferred by a “pre-pandemic” influenza vaccine is underway at Baylor College of Medicine in Houston (USA). Investigators are evaluating whether imiquimod cream, which is commonly used to treat genital warts and certain skin cancers, can boost the body’s immune response to an H5N1 influenza vaccine. The trial is enrolling 50 healthy adults ages 18-50 years. 

Read more